From 1 May 2022 a Pharmaceutical Benefit Scheme (PBS) listing for the treatment of Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) will be available for Australians with chronic fibrosing ILDs.
This treatment is the only anti-fibrotic indicated and reimbursed for this condition in Australia.
“PF-ILD severely impacts the quality of life of Australians living with this devastating disease. Having a treatment option available and reimbursed not only offers people living with this condition hope, but also their families and carers too.” Lung Foundation Australia CEO Mark Brooke said.
The addition of this treatment onto the PBS is another fantastic step to improving access to life-changing treatments for Australians.
Lung Foundation Australia will continue our work to advocate for accessible and affordable treatments for all Australians living with lung disease.
To find out more, follow the link below.
